LT-171-861 News - LARVOL Sigma

|||||||||| LT-171-861 / China Pharmaceutical University
Journal, PARP Biomarker: Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP Inhibitor in multiple myeloma. (Pubmed Central) - Nov 21, 2021
Moreover, Olaparib, a PARP inhibitor, could enhance the antitumor effect of LT-171-861 in suppressing tumor growth in MM xenografted nude mice. Taken together, our results demonstrated that LT-171-861 showed a promising therapeutic potential for MM and had an additional lethal effect with PARP inhibitors.

|||||||||| LT-171-861 / China Pharmaceutical University
Preclinical, Journal: LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. (Pubmed Central) - Aug 7, 2021
We also show the efficacy of LT‑171-861 in a subcutaneous implantation model and a bone marrow engrafted model in vivo, where administration of LT-171-861 led to almost complete tumor regression and increased survival. Overall, this study not only identifies LT-171-861 as a potent FLT3 inhibitor, but also provides a rationale for the upcoming clinical trial of LT-171-861 in patients with AML and FLT3-ITD mutations.



	Diseases Companies Products Productz Mechanisms of Action Sites